logo
logo

Arrowhead Pharmaceuticals Appoints Daniel Apel As Chief Financial Officer

Apr 15, 20254 months ago

Position

Chief Financial Officer

Company

Arrowhead

Daniel Apel
PasadenaManufacturing

Description

Effective May 13, 2025, Daniel Apel will succeed Ken Myszkowski as the Chief Financial Officer of Arrowhead Pharmaceuticals. Ken Myszkowski is retiring after 16 years but will assist in the transition.

Company Information

Company

Arrowhead

Location

Pasadena, California, United States

About

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

Related People

Sign in to view contact details

Sign in to view contact details

Executive Insights

Based on hiring data
New executive impact window
87% of new executives make significant technology decisions within first 100 days
Budget influence
C-level executives control 73% of technology spending decisions
Transformation catalyst
65% of new senior hires launch digital transformation initiatives
Vendor review timeline
New executives typically review existing vendors within 6 months